Hold ACN at benchmark weight; do not add at $198-200 and do not trim pending $193-195 technical resolution
Analysts unanimously converge on Hold as the directional call, with the Research Manager's plan, trader's proposal, and prior-decision reflection log all aligning on minimum intervention. The aggressive analyst's fundamental thesis (7.4% revenue re-acceleration, $3.80 Q3 FY26 EPS, 17% FCF margin, 26% ROE, 13.6x forward earnings) is correct but overstates asymmetry at 3:1 versus the neutral/conservative 1.5-2:1. The conservative analyst correctly flags the Oct 1 spike as a buying climax (5x average volume, RSI 70), the Oct 2 reversal as Wyckoff distribution, and notes the EPS comparison is cherry-picked ($3.80 vs quarters with $615M and $308M charges; clean YoY is +8.9%). The $923M cumulative goodwill charge and $25.3B balance is a real risk, not yet an active bleed. The post-spike +15.8% regime-shift conviction has already failed (-7.1% alpha forfeit on prior Hold), and the 9/30 reflection is dispositive: in the 30-60 days following a 99th-percentile single-session move, treat technical confirmation as suspect. The two-sided triggers from the neutral analyst provide a defined reaction framework without pre-committing to a directional bet the tape has not yet confirmed.
| Position | Action |
|---|---|
| Post-climactic reversal period (30-60 days following 99th-percentile single-session move) | Treat technical confirmation as suspect; avoid aggressive additions |
| Prior Hold decision with failed regime-shift thesis (-7.1% alpha forfeit) | Do not add full size at $198-200; avoid compounding prior error |
| Pre-earnings Underweights on quality compounders at trough multiples | Avoid trimming; floor-protection carry absorbs 1-3% drawdowns |
| Structural floor intact (13.6x forward earnings, 26% ROE, 17% FCF margin, net cash) | Maintain position; do not reduce exposure |
Accenture's 15% decline has already absorbed bearish sentiment, creating an asymmetric risk-reward at current levels with revenue inflecting to 7.4% growth and the stock trading at a historical discount to its mid-20s PE range.
| Indicator | Value | Signal |
|---|---|---|
| Close | 198.90 | neutral |
| 10 EMA | 188.87 | bullish |
| 50 SMA | 180.09 | bullish |
| 200 SMA | 193.46 | neutral |
| MACD | +3.40 | bullish |
| MACD Signal | +2.13 | bullish |
| MACD Histogram | +1.27 | bullish |
| RSI (14) | 59.1 | neutral |
| Bollinger Upper Band | 204.01 | neutral |
| Bollinger Middle Band (20 SMA) | 185.30 | neutral |
| Bollinger Lower Band | 166.59 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Close <$193 with RSI <50
Then: Trim position
EV: $235-260 over 6-12 months · concedes: ACN is off 15% over the last year; Death cross on the chart (50 SMA below 200 SMA); 96% Polymarket probability of no Fed cuts makes duration-sensitive multiples uncomfortable; Goodwill of $25.3B (37% of assets) represents concentration risk; Aug 2025 and Nov 2025 impairment charges were absorbed but remain a risk
ACN's "re-acceleration" is a head-fake driven by a blow-off spike, biased EPS comparisons, and macro tailwinds that are already reversing—not a genuine inflection. SELL at $198-200 with $170-180 target as multiple compression, goodwill impairments, and GenAI displacement compound.
EV: $170-180 over 3-6 months · concedes: ACN has a strong brand and the consulting market is expanding, but the timing is wrong given the macro headwinds; The $3.80 EPS print is real growth (+8.9% YoY on clean quarters)—but the comparison is cherry-picked and the forward estimates are at risk of cuts
→ vs conservative: Anchored to technical levels set during broken post-mid-June regime; waiting for 193-195 test means paying 5-10% premium for information already available; 200 SMA 'rolling over' and -6.3% intraday drop misread as distribution when it's actually healthy post-spike digestion
→ vs neutral: 'Balanced risk reward' is euphemism for indecision; down 15% with revenue re-accelerating to 7.4%, EPS at 3.80 (highest in 5 years), 26% ROE, 17% FCF margin, 13.6x PE, and $8.3B buyback is not neutral — it's a gift; refusing to make a call is hiding behind sentiment data while ignoring fundamentals already priced in
| neutral |
| ATR | 9.96 | neutral |
| Rating | HOLD | neutral |
Support: 193.46 · 185.3 · 180.09 · 174.47 · 166.59 | Resistance: 204.01 · 213.31 · 227
ACN staged a news-driven blow-off spike (+15.8%) to $212.30 on Oct 1, then retreated -6.3% to $198.90 on Oct 2 on above-average volume (~10M shares). The MACD issued a fresh bullish crossover (histogram +1.27), RSI cooled from 70.0 overbought to 59.1, and price reclaimed the 200 SMA at $193.46—but failed to hold above it as a support. The 50 SMA remains below the 200 SMA, keeping the death cross technically in effect. Overall stance is HOLD; a 2–3 day retest of the $193–$195 zone will determine whether to shift bias to tactical BUY (successful bounce) or back to SELL/cautious HOLD (daily close below $193 with RSI < 50). ATR of $9.96 implies a 2×ATR stop near $179, coinciding with the 50 SMA at $180.09.
Market Cap
$121.7B
PE Ratio (TTM)
15.87
Forward PE
13.56
PEG Ratio
1.54
Price to Book
3.82
EPS (TTM)
$12.53
Forward EPS
$14.66
Dividend Yield
3.07%
52-Week High
$291.09
52-Week Low
$118.15
50-Day Moving Avg
$178.89
200-Day Moving Avg
$196.29
TTM Revenue
$74.18B
FY2025 Revenue
$69.67B
FY2025 Net Income
$7.68B
FY2025 Net Margin
11.0%
TTM Gross Margin
~32.1%
Operating Margin (TTM)
15.33%
Net Profit Margin (TTM)
11.28%
EBITDA
$14.07B
Return on Equity (ROE)
26.03%
Return on Assets
10.53%
TTM FCF
~$12.58B
FCF Margin
~17%
Current Ratio
1.43
Debt/Equity
0.26
Net Debt
($1.78B)
Total Assets (Q3 FY26)
$68.81B
Stockholders Equity (Q3 FY26)
$31.89B
Total Debt (Q3 FY26)
$8.39B
Cash & Equivalents (Q3 FY26)
$10.17B
Goodwill
$25.3B
Shareholder Returns (FY25)
$8.3B/year
CapEx
~0.8% of revenue
Strengths
Concerns
Accenture plc (ACN) is a high-quality IT services leader with exceptional fundamentals including 26% ROE, 17% FCF margin, and a net cash balance sheet. The company returned $8.3B to shareholders in FY25 through buybacks and dividends while maintaining minimal CapEx (~0.8% of revenue). Revenue re-accelerated to 7.4% in FY25, and Q3 FY26 showed strong momentum with EPS of $3.80 (highest in recent quarters). The rating is HOLD given the reasonable but not compelling valuation (15.9x PE), technical weakness below the 200-DMA, and macro uncertainty around IT services demand — new positions may wait for a pullback toward the 50-DMA ($178) or clearer technical breakout.
Macro: The macro backdrop features a higher-for-longer rate regime: Polymarket prices 96% probability of NO Fed rate cuts in 2026, creating structural valuation headwinds for long-duration growth/consulting names like ACN with premium P/E multiples (~mid-20s historically). A September jobs report miss has eased Treasury yields and supported a short-term tech rally as Fed-hike odds faded. However, the Iran-war inflation channel is active beyond oil—supply chains, defense-linked commodities, and risk premia are leaking into CPI/PCE—keeping the Fed's hands tied despite only 3% probability of formal US-Iran war by year-end. The US recession probability by end-2026 sits at just 8% on Polymarket, supporting a soft-landing/no-recession base case favorable for enterprise consulting spend. FRED macro data was unavailable (API not configured), limiting primary time-series analysis; macro commentary is anchored in news coverage and prediction-market probabilities instead.